Who are TLC599's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oral chemotherapy, Tislelizumab plus Carboplatin and Paclitaxel, docetaxel plus oxaliplatin and capecitabine, Short Course Adjuvent Chemotherapy, Taxanes plus Carboplatin, induction chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tlc599.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

TLC599 — Competitive Intelligence Brief

TLC599 (TLC599) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapeutic agent. Area: Oncology.

phase 3 chemotherapeutic agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TLC599 (TLC599) — Taiwan Liposome Company. TLC599 is a liposomal formulation of a chemotherapeutic agent.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TLC599 TARGET	TLC599	Taiwan Liposome Company	phase 3	chemotherapeutic agent
Oral chemotherapy	Oral chemotherapy	All India Institute of Medical Sciences	phase 3	Chemotherapeutic agent	Topoisomerase II
Tislelizumab plus Carboplatin and Paclitaxel	Tislelizumab plus Carboplatin and Paclitaxel	RemeGen Co., Ltd.	phase 3	PD-1 inhibitor and chemotherapeutic agents	PD-1
docetaxel plus oxaliplatin and capecitabine	docetaxel plus oxaliplatin and capecitabine	LiNing	phase 3	chemotherapeutic agents
Short Course Adjuvent Chemotherapy	Short Course Adjuvent Chemotherapy	Trans Tasman Radiation Oncology Group	phase 3	Chemotherapeutic agent
Taxanes plus Carboplatin	Taxanes plus Carboplatin	Shanghai Jiao Tong University School of Medicine	phase 3	Taxane and platinum-based chemotherapeutic agent	Microtubules and DNA
induction chemotherapy	induction chemotherapy	Zhejiang Cancer Hospital	phase 3	Chemotherapeutic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapeutic agent class)

Korea Cancer Center Hospital · 1 drug in this class
Taiwan Liposome Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TLC599 — Competitive Intelligence Brief. https://druglandscape.com/ci/tlc599. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab